Rheumatoid Arthritis

Phase II clinical trial of AGIX-4207 initiated

Published in Women's Health Weekly, October 31st, 2002

AtheroGenics, Inc., (AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, has announced the initiation of a phase II clinical trial of AGIX-4207 for the treatment of rheumatoid arthritis (RA).

The phase II clinical trial will evaluate the effect of orally administered AGIX-4207, on biomarkers of inflammation in patients currently being treated with infusions of infliximab (Remicade).

The multicenter, double-blind, randomized, placebo-controlled, phase II trial will determine the effect of two AGIX-4207 dosing regimens on established biomarkers of RA, including erythrocyte sedimentation rate (ESR) and highly...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-10-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry